Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid

Journal of Alzheimer's Disease

Volumn 26, Issue 2, 2011, Pages 255-262

  Schipke, Carola G ^a   Jessen, Frank ^b,h   Teipel, Stefan ^c,h   Luckhaus, Christian ^d   Wiltfang, Jens ^e   Esselmann, Hermann ^e   Frölich, Lutz ^f   Maier, Wolfgang ^b,h   Rüther, Eckart ^g   Heppner, Frank L ^a   Prokop, Stefan ^a   Heuser, Isabella ^a   Peters, Oliver ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; amyloid protein; biomarkers; cerebrospinal fluid; protein stability; tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; BIOMATERIAL; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUMBAR PUNCTURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; RELIABILITY;

EID: 80052795071     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110329     Document Type: Article

References (23)

1. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 46, 235-240.
2. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Abeta (40) and Abeta (42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 357-367.
3. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
4. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Ruther E, Kornhuber J, Wiltfang J (2007) Validation of amyloid-beta peptides in CSF diagnosisofneurodegenerativedementias. Mol Psychiatry 12, 671-680. (Pubitemid 46998250)
5. Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, Blankenstein MA, Scheltens, Pijnenburg YA (2010) Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 20, 445-452.
6. Lewczuk P, Kornhuber J, Wiltfang J (2006) The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics. J Neural Transm 113, 1075-1080. (Pubitemid 44079939)
7. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, Scheltens P, Blankenstein MA (2005) Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 51, 189-195. (Pubitemid 40024030)
8. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, Andreasen N, Zetterberg H, Andreasson U, Blennow K (2010) Confounding factors influencing amyloid Beta concentrationin cerebrospinalfluid. Int J Alzheimers Dis 2010, pii: 986 310.
9. Schipke CG, Prokop S, Heppner FL, Heuser I, Peters O (2011) Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's diseaseinhuman cerebrospinal fluid. Dement Geriatr Cogn Disord 31, 139-145.
10. Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, Frolich L, Schroder J, Peters O, Jessen F, Luckhaus C, Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R, Bruckmoser R, Kornhuber J, Lewczuk P (2007) Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low-and high-CSF A beta 40 load. J Neurochem 101, 1053-1059. (Pubitemid 46683864)
11. Kornhuber J, Schmidtke K, Frolich L, Perneczky R, Wolf S, Hampel H, Jessen F, Heuser I, Peters O, Weih M, Jahn H, Luckhaus C, Hull M, Gertz HJ, Schroder J, Pantel J, Rienhoff O, Seuchter SA, Ruther E, Henn F, Maier W, Wilt-fang J (2009) Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord 27, 404-417.
12. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wilt-fang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 52, 1555-1562. (Pubitemid 29220627)
13. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 1914-1922.
14. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L (2005) Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease Neuroimaging Initiative (ADNI). Alzheimers Dement 1, 55-66. (Pubitemid 43348857)
15. Visser PJ, Verhey FR, Boada M, Bullock R, De Deyn PP, Frisoni GB, Frolich L, Hampel H, Jolles J, Jones R, Minthon L, Nobili F, Olde Rikkert M, Ousset PJ, Rigaud AS, Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki M, Vellas B, Wahlund LO, Wilcock G, Winblad B (2008) Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study. Neuroepidemi-ology 30, 254-265. (Pubitemid 351871657)
16. Petzold A, Chapman MD, Schraen S, Verwey NA, Pasquier F, Bombois S, Brettschneider J, Fox NC, von Arnim CA, Teunissen C, Pijnenburg Y, Riepe MW, Otto M, Tumani H, Scheltens P, Buee L, Rossor MN (2010) An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Exp Neurol 223, 432-438.
17. Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, Petereit HF, Tumani H, Gerritzen A, Oschmann P, Schroder J, Schonknecht P, Zim-mermann K, Hampel H, Burger K, Otto M, Haustein S, Herzog K, Dannenberg R, Wurster U, Bibl M, Maler JM, Reubach U, Kornhuber J, Wiltfang J (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409, 1-4. (Pubitemid 44740057)
18. Anesi A, Rondanelli M, d'Eril GM (1998) Stability of neu-roactive amino acids in cerebrospinal fluid under various conditions of processing and storage. Clin Chem 44, 2359-2360. (Pubitemid 28511760)
19. Seilheimer B, Bohrmann B, Bondolfi L, Muller F, Stuber D, Dobeli H (1997) The toxicityofthe Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. J Struct Biol 119, 59-71. (Pubitemid 27294721)
20. von Bergen M, Barghorn S, Biernat J, Mandelkow EM, Mandelkow E (2005) Tau aggregation is driven by a transition from random coilto beta sheet structure.Biochim Biophys Acta 1739, 158-166. (Pubitemid 40018535)
21. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91, 12243-12247. (Pubitemid 24368641)
22. Mukrasch MD, Bibow S, Korukottu J, Jeganathan S, Biernat J, Griesinger C, Mandelkow E, Zweckstetter M (2009) Structural polymorphism of 441-residue tau at single residue resolution. PLoS Biol 7, e34.
23. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 81, 608-610.